AbCellera Biologics Inc
Company Profile
Business description
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Contact
150 W 4th Avenue
VancouverBCV5Y 1G6
CANT: +1 604 559-9005
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
562
Stocks News & Analysis
stocks
A closer look at US tech earnings
stocks
Cheap ASX energy share lifts earnings guidance on stronger output
stocks
ASX listed bank overvalued despite strong earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,909.60 | 42.50 | -0.47% |
| CAC 40 | 7,978.85 | 77.53 | -0.96% |
| DAX 40 | 23,997.45 | 352.83 | -1.45% |
| Dow JONES (US) | 49,425.40 | 279.07 | -0.56% |
| FTSE 100 | 10,242.59 | 26.84 | -0.26% |
| HKSE | 26,347.91 | 58.93 | -0.22% |
| NASDAQ | 25,969.53 | 304.60 | -1.16% |
| Nikkei 225 | 62,742.57 | 324.69 | 0.52% |
| NZX 50 Index | 13,080.33 | 130.15 | -0.99% |
| S&P 500 | 7,361.63 | 51.21 | -0.69% |
| S&P/ASX 200 | 8,670.70 | 40.60 | -0.47% |
| SSE Composite Index | 4,214.49 | 10.53 | -0.25% |